IRIDEX (IRIX) Sidoti's Year End Virtual Investor Conference summary

Strategic vision and product innovation

• Focus on transforming laser-based eye care with non-invasive, clinically proven technologies for glaucoma and retinal disorders.

• Comprehensive product portfolio covers both retina and glaucoma, leveraging MicroPulse technology for minimal tissue damage.

• New Pascal platform and software options enhance safety and efficacy, targeting replacement opportunities as older systems reach end of life.

• EndoProbe line provides recurring revenue through single-use devices for surgical procedures.

• Global presence with direct sales in the U.S. and distribution in over 40 countries, supporting scalable growth.

Market opportunity and clinical differentiation

• Retina market growth driven by rising diabetic eye disease and aging populations, with 8 million procedures annually.

• MicroPulse technology offers clinical advantages over traditional lasers, reducing scarring and thermal damage.

• Glaucoma business targets moderate and mild patients, expanding beyond late-stage treatment and tapping into a $700 million OUS market.

• Clinical data shows sustained IOP reduction and repeatable, non-incisional therapy, with long-term efficacy.

• Stable reimbursement environment and favorable ROI for capital equipment drive adoption in ASCs and hospitals.

Financial performance and operational efficiency

• 2024 revenue reached $49 million, with glaucoma margins at 71% and retina at 41%.

• Significant cost reductions achieved by halving the sales team and reducing OpEx by $2.3 million.

• Positive adjusted EBITDA and plans for cash flow positivity in Q4, with operating income and cash flow positive targets for 2026.

• Contract manufacturing transition planned to expand gross margins by 350-500 basis points by late FY2026 or early 2027.

• Additional cost savings expected from relocating facilities and moving G&A functions out of California.